130P - Locoregional treatment in de novo stage IV breast cancer: A retrospective study of Chinese population

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Metastatic
Surgery and/or Radiotherapy of Cancer
Presenter Wenyan Wang
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors W. Wang1, X. Wang1, X. Wang1, J. Liu1, J. Gao1, P. Zhang2, D. Zhao3
  • 1Breast Surgical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
  • 2Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
  • 3Abdominal Surgical Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN

Abstract

Background

The role of locoregional therapy of the primary in patients presenting with de novo stage IV breast cancer remains controversial. The aim of the present study was to evaluate the impact of locoregional resection and radiotherapy on survival of Chinese women with stage IV breast cancer.

Methods

The retrospective study included Chinese patients with de novo stage IV breast cancer in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences between January 1st 2001 and November 30th 2015.Patients were identified as having local surgery if the date of breast-conserving surgery or mastectomy was within 1 year of initial breast cancer diagnosis date. All patients were treated with primary chemotherapy treatment. The target volume for locoregional radiotherapy was the chest wall and draining lymphatics and regimen delivered 50 Gy in 25 fractions. Kaplan-Meier curves were reported for overall survival (OS), and distant progression free survival (DPFS). Log-rank test was used to compare the difference in groups. Cox proportional models were fitted for multivariate analysis.

Results

Of the 157 patients who presented with stage IV breast cancer, 66 (42.0%) underwent surgery, 52 (33.1%) patients received locoregional radiotherapy. Median age was 58.0 years (range 28 to 83 years). Median follow up time was 44.5 months (range 5 to 180 months). Median OS and DPFS were 36 months and 21 months. Patients in the surgery group had longer OS and DPFS than non-surgery group (5-y OS 93.3% vs 60.4%, P = 0.002; 5-y DPFS 57.6% vs 26.4%, P 

Conclusions

Locoregional surgical treatment and radiotherapy were associated with improved survival in Chinese patients with stage IV breast cancer. Response to systemic therapy and PR status may be impact factors for predicting prognosis.

Clinical trial indentification

Legal entity responsible for the study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, China

Funding

Chinese Ministry of Science, National Program on Key Basic Research Project (973 Program)

Disclosure

All authors have declared no conflicts of interest.